Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Learn more about whether Corcept Therapeutics Incorporated or Novo Nordisk A/S is a better investment based on AAII's A+ ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...